Davunetide (acetate)
(Synonyms: AL-108, NAP, NAPVSIPQ) 目录号 : GC49913
A neuroprotective ADNP-derived peptide
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Davunetide is a neuroprotective peptide derived from activity-dependent neuroprotective protein (ADNP).1 It promotes tubulin assembly in a cell-free assay when used at a concentration of 1 fM.2 Davunetide (1 fM) protects against cytotoxicity induced by tetrodotoxin , a peptide derived from amyloid-β (Aβ), or zinc in isolated neonatal cerebral cortical cells.1,2 Intravitreal administration of davunetide (4 µl of a 100 µg/ml solution) inhibits increases in cleaved caspase-3 and decreases in Bcl-2 levels in retina isolated from streptozotocin-induced diabetic rats.3 It improves survival in a superoxide dismutase 1 mutant (SOD1G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS) when administered at 10 µg/animal.4 Davunetide prevents decreases in brain choline acetyltransferase (ChAT) activity and prevents memory deficits in the Morris water maze in an Apoe-/- mouse model of neurodegeneration.1
1.Bassan, M., Zamostiano, R., Davidson, A., et al.Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptideJ. Neurochem.72(3)1283-1293(1999) 2.Divinski, I., Mittelman, L., and Gozes, I.A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxicationJ. Biol. Chem.279(27)28531-28538(2004) 3.Scuderi, S., D’Amico, A.G., Castorina, A., et al.Davunetide (NAP) protects the retina against early diabetic injury by reducing apoptotic deathJ. Mol. Neurosci.54(3)395-404(2014) 4.Jouroukhin, Y., Ostritsky, R., Assaf, Y., et al.NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: Protection against impairments in axonal transportNeurobiol. Dis.5679-94(2013)
| Cas No. | SDF | Download SDF | |
| 别名 | AL-108, NAP, NAPVSIPQ | ||
| Canonical SMILES | O=C([C@H]1N(CCC1)C([C@H](C)NC([C@@H](N)CC(N)=O)=O)=O)N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N2[C@@H](CCC2)C(N[C@H](C(O)=O)CCC(N)=O)=O)=O)=O)=O.CC(O)=O | ||
| 分子式 | C36H60N10O12 • XC2H4O2 | 分子量 | 824.9 |
| 溶解度 | DMF: 1 mg/ml,DMSO: 1 mg/ml,Ethanol: insol,PBS (pH 7.2): 10 mg/ml | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2123 mL | 6.0613 mL | 12.1227 mL |
| 5 mM | 0.2425 mL | 1.2123 mL | 2.4245 mL |
| 10 mM | 0.1212 mL | 0.6061 mL | 1.2123 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。